We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Shire | LSE:SHP | London | Ordinary Share | JE00B2QKY057 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4,690.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
04/8/2017 08:50 | 4th aug RBC outperform tp $213 cut from $214 4th aug HSBC hold tp 4480p up from 4450p | philanderer | |
04/8/2017 08:48 | For anyone interested a few recent decent articles on Seeking Alpha looking at SHP in detail. | essentialinvestor | |
04/8/2017 08:46 | Morning Phil, intend to add in small amounts. | essentialinvestor | |
04/8/2017 08:45 | Morning EI , luck with those. So , this not helping the shareprice now.. :-S FT. Analysts at Deutsche Bank said the review of the neuroscience business should not “shock investors but is likely to raise a debate over possible use of proceeds should any cash be generated and management of any earnings dilution [ie deleveraging v M&A]”. | philanderer | |
04/8/2017 08:40 | It's fascinating looking at the recent GSK statement where they are moving away from rare diseases, the very area Shire focus on. | essentialinvestor | |
04/8/2017 08:36 | My entry level approaching 4000 | a2584728 | |
04/8/2017 08:31 | Bought a few. | essentialinvestor | |
04/8/2017 08:28 | Think it's still the Roche potential treatment weighing on sentiment. | essentialinvestor | |
04/8/2017 08:09 | Dollar related, weak dollar is not good for Pharma | bigboots | |
04/8/2017 08:00 | It's a weird performance for sure. Can't see any downgrades 4th aug JP Morgan Caz overweight - 4th aug Deutsche buy tp 6000p 4th aug Credit Suisse outperform tp 5350p reiterations | philanderer | |
04/8/2017 07:17 | Sterling strength? Brexit obliterated sterling in the short and medium term. Plus biotechs are going greats guns - look at IBB the biotech index. In my view SHP has many tailwinds and that's why I got involved, but tbh sitting on a small loss at present. Gutted. | ruethewhirl | |
03/8/2017 23:19 | The ADRs are near 40% off their high of two years ago. Healthcare out of favour,summer lull,sterling strength,technical weakness...you can seek any number of explanations but you'll be chasing your tail to explain this continued underperformance.I see that Inmarsat got given the roller coaster ride today too.I think I'll blame algorithmic trading.Since I have no intention of selling Shire though,I don't need to struggle too hard to make sense of it all. | steeplejack | |
03/8/2017 22:21 | Market report: Elsewhere in healthcare, pharmaceuticals firm Shire has launched a review which could see it split in half. The company's neurosciences division is responsible for around a fifth of its sales and is a big earner in America, where its ADHD drugs are hugely popular. Chief executive Flemming Ornskov described it as an 'incredibly strong business that could stand alone'. New York and London are both thought to be contenders to host the new business. A separation would leave Shire free to put all its energy into its rare diseases arm. This is the key money-spinner and has made valuable breakthroughs in immunology, haematology, internal medicine, eye ailments, oncology and anti-virals. 'We are at an exciting inflection point,' Ornskov said. Shares slipped 2 per cent, or 82p, to 4118p. Read more: | philanderer | |
03/8/2017 20:31 | When I flicked through the results I thought oh great finally we will rally. | ruethewhirl | |
03/8/2017 20:29 | Takeover rumours are exactly that. Rumours. I held onto Aveva for an entire year because of rumours AND an approach, which then fell through. | ruethewhirl | |
03/8/2017 20:02 | Closed down 3.4% in US | greenrichard | |
03/8/2017 17:54 | Some platforms such as Interactive Investor showing a closing share price of 4205p. Lots of buys showing up to 1711 | justiceforthemany | |
03/8/2017 17:34 | Amazing that the share price fell today after positive results and a rise in EPS to $15/share ADS or $5/share for us. This is giving a P/E of only 10.7 Pfizer, Eli Lilly, Roche, Novartis all have market caps >$200Bn so could easily swallow Shire and all trade with P/E's around 30. | justiceforthemany | |
03/8/2017 17:30 | 5300p/share? RUMOURED BID FOR SHIRE Evening Standard The City rumour mill was in full flow today as deal-hungry traders suggested drug-maker Shire was back in play. Gossips said some of the biggest drugs firms in Europe and the US have hired advisers ahead of a possible tilt at the Dublin-based company. They added that Shire, fearing lowball bids, had hired defence advisers. Earlier this month, the FTSE 100 company’s chief executive Flemming Ornskov hinted that investors were valuing Shire too low after a 10% fall from the share price this year. He pointed to the healthy pipeline of drugs, including for ADHD and haemophilia, which came as part of the £22 billion acquisition of Baxalta. Shire accepted a £32 billion cash and shares bid in 2014 from US rival AbbVie worth around 5300p per share before a clampdown on tax inversion deals scuppered the takeover. The shares now languish at 4284.5p, up another 63.31p, or 1.5%, today after gaining ground yesterday, valuing the firm at £39 billion. Shire declined to comment on the speculation. | justiceforthemany | |
03/8/2017 16:18 | 'Shire may spin off ADHD drugs business' The pharma company upgraded guidance after strong first half Analysts at Jefferies said a spin-off of the ADHD business had been mooted many times, but it now seemed reasonable given Baxalta had catapulted the transition into rare diseases, and Mydayis would extend the ADHD portfolio’s lifecycle beyond Vyvanse’s 2023-24E expiries. | philanderer | |
03/8/2017 14:09 | I think it's a mix of: healthcare out of favour right now so profit taking here not being full offset by new buyers strategic review creates uncertainty I am surprised about the dip below open because they have good results here and they are upping their forecast A couple of analysts on the call obviously hostile | romeike | |
03/8/2017 14:05 | That jump was short lived :-O Conference call not gone down too well ?? 'Shire ups earnings guidance as second quarter sales surge' | philanderer | |
02/8/2017 16:53 | Q2 results at midday rtomorrow | philanderer | |
28/7/2017 16:42 | SHP and BRBY the only ones up for me this week out of twenty . Cr@p five days. | philanderer |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions